Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the cancer therapy landscape due to long-term benefits in patients with advanced metastatic disease. However, robust predictive biomarkers for response are still lacking and treatment resistance is not fully understood. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Harel, Michal, Lahav, Coren, Jacob, Eyal, Dahan, Nili, Sela, Itamar, Elon, Yehonatan, Raveh Shoval, Shani, Yahalom, Galit, Kamer, Iris, Zer, Alona, Sharon, Ofer, Carbone, David P, Dicker, Adam P, Bar, Jair, Shaked, Yuval
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207924/
https://www.ncbi.nlm.nih.gov/pubmed/35718373
http://dx.doi.org/10.1136/jitc-2022-004582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207924/
https://www.ncbi.nlm.nih.gov/pubmed/35718373
http://dx.doi.org/10.1136/jitc-2022-004582

Ejemplares similares